GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (STU:7F0) » Definitions » Equity-to-Asset

Fulgent Genetics (STU:7F0) Equity-to-Asset : 0.93 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Fulgent Genetics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Fulgent Genetics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €1,082.2 Mil. Fulgent Genetics's Total Assets for the quarter that ended in Dec. 2024 was €1,165.1 Mil. Therefore, Fulgent Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.93.

The historical rank and industry rank for Fulgent Genetics's Equity-to-Asset or its related term are showing as below:

STU:7F0' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.81   Med: 0.92   Max: 0.95
Current: 0.93

During the past 11 years, the highest Equity to Asset Ratio of Fulgent Genetics was 0.95. The lowest was 0.81. And the median was 0.92.

STU:7F0's Equity-to-Asset is ranked better than
97.79% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.63 vs STU:7F0: 0.93

Fulgent Genetics Equity-to-Asset Historical Data

The historical data trend for Fulgent Genetics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Equity-to-Asset Chart

Fulgent Genetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.91 0.91 0.92 0.93

Fulgent Genetics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.92 0.92 0.92 0.93

Competitive Comparison of Fulgent Genetics's Equity-to-Asset

For the Diagnostics & Research subindustry, Fulgent Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Equity-to-Asset falls into.


;
;

Fulgent Genetics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Fulgent Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=1082.233/1165.066
=0.93

Fulgent Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=1082.233/1165.066
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (STU:7F0) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Fulgent Genetics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics Business Description

Traded in Other Exchanges
Address
4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics Headlines

No Headlines